WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317864

CAS#: 72509-76-3

Description: Felodipine is a calcium channel blocker (calcium antagonist), used to control hypertension. Felodipine prevents calcium from being released within the muscle cells of the small arteries and thereby causes the muscles to relax and the arteries to dilate or expand. Dilation of arteries reduces blood pressure. Felodipine has little or no effect on the muscles of veins or the heart. Felodipine was approved by the FDA in 1991.

Price and Availability


USD 250
USD 850
Ask price

USD 350
USD 1550

USD 550
Ask price

Felodipine, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 317864
Name: Felodipine
CAS#: 72509-76-3
Chemical Formula: C18H19Cl2NO4
Exact Mass: 383.0691
Molecular Weight: 384.2538
Elemental Analysis: C, 56.26; H, 4.98; Cl, 18.45; N, 3.65; O, 16.66

Synonym: Felodipine, Agon, Felo-Puren, Felobeta, Felocor, Felodipin, Felodur Felogamma, Fensel, Flodil, Modip, Munobal, Perfudal, Plendil, Renedil

IUPAC/Chemical Name: (RS)-3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate


InChi Code: InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Uesawa Y, Takeuchi T, Mohri K. Publication bias on clinical studies of pharmacokinetic interactions between felodipine and grapefruit juice. Pharmazie. 2010 May;65(5):375-8. Review. PubMed PMID: 20503932.

2: Cvetković RS, Plosker GL. Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension. Drugs. 2005;65(13):1851-68. Review. PubMed PMID: 16114982.

3: Haria M, Plosker GL, Markham A. Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension. Drugs. 2000 Jan;59(1):141-57. Review. PubMed PMID: 10718104.

4: Little WC, Cheng CP, Elvelin L, Nordlander M. Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. Cardiovasc Drugs Ther. 1995 Oct;9(5):657-63. Review. PubMed PMID: 8573548.

5: Dahlöf B, Andersson OK. A felodipine-metoprolol extended-release tablet: its properties and clinical development. J Hum Hypertens. 1995 Jul;9 Suppl 2:S43-7. Review. PubMed PMID: 7562899.

6: Trenkwalder P, Elmfeldt D. Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs--the rationale and benefits of combining felodipine and metoprolol. J Hum Hypertens. 1995 Jul;9 Suppl 2:S37-42. Review. PubMed PMID: 7562898.

7: Gradman AH. The evolving role of calcium channel blockers in the treatment of angina pectoris: focus on felodipine. Can J Cardiol. 1995 Apr;11 Suppl B:14B-21B. Review. PubMed PMID: 7728649.

8: Purcell H, Coats A. Structural changes in hypertension, the potential for their prevention, arrest and reversal: a focus on felodipine. Br J Clin Pract. 1994 Nov-Dec;48(6):311-6. Review. PubMed PMID: 7848795.

9: Walton T, Symes LR. Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension. Clin Pharm. 1993 Apr;12(4):261-75. Review. PubMed PMID: 8458178.

10: Gradman AH. Treatment of hypertension with felodipine in patients with concomitant diseases. Clin Cardiol. 1993 Apr;16(4):294-301. Review. PubMed PMID: 8458109.

11: Faulds D, Sorkin EM. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in older patients. Drugs Aging. 1992 Sep-Oct;2(5):374-88. Review. PubMed PMID: 1392220.

12: Todd PA, Faulds D. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs. 1992 Aug;44(2):251-77. Review. PubMed PMID: 1382018.

13: Elmfeldt D, Nordlander M, Edgar B. Renal effects of felodipine--a review. Kidney Int Suppl. 1992 May;36:S54-60. Review. PubMed PMID: 1614069.

14: DeQuattro V. Efficacy and safety of felodipine, a new dihydropyridine calcium channel blocker, in elderly hypertensive patients. Clin Exp Hypertens A. 1992;14(6):965-87. Review. PubMed PMID: 1424224.

15: Dunselman PH, Edgar B. Felodipine clinical pharmacokinetics. Clin Pharmacokinet. 1991 Dec;21(6):418-30. Review. PubMed PMID: 1782737.

16: Yedinak KC, Lopez LM. Felodipine: a new dihydropyridine calcium-channel antagonist. DICP. 1991 Nov;25(11):1193-206. Review. PubMed PMID: 1763537.

17: Lorimer AR, Pringle SD. The safety of felodipine. J Cardiovasc Pharmacol. 1990;15 Suppl 4:S85-9. Review. PubMed PMID: 1693736.

18: Morgan TO. A review of the antihypertensive effects of felodipine alone or in combination. J Cardiovasc Pharmacol. 1990;15 Suppl 4:S76-84. Review. PubMed PMID: 1693735.

19: Reid JL. Dose-plasma concentration--effect relationship of felodipine in essential hypertension: a review. J Cardiovasc Pharmacol. 1990;15 Suppl 4:S50-6. Review. PubMed PMID: 1693728.

20: Lund-Johansen P. Hemodynamic effects of felodipine in hypertension: a review. J Cardiovasc Pharmacol. 1990;15 Suppl 4:S34-9. Review. PubMed PMID: 1693723.